NCT05446467 - Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

March 1, 2026

Study Completion Date

June 1, 2026

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

COMBINATION_PRODUCT

pembrolizumab+cisplatin + 5-FU

ivgtt, pembrolizumab 200mg d1+cisplatin20 mg/m2 qd d1-d3 + 5-fluorouracil 3000mg/m2 last for 120hours, six circles. Subjects will undergo surgery after receiving neoadjuvant chemotherapy within 3 weeks, followed by adjuvant therapy and pembrolizumab alone maintenance treatment.

Trial Locations (7)

266555

NOT_YET_RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

310014

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

Unknown

RECRUITING

Sir Run Run Shaw Hospital School of Medicine,Zhejiang University, Hangzhou

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

Ningbo Medical Center Lihuili Hospital, Ningbo

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors

lead

Zhejiang Provincial People's Hospital

OTHER